22ND CENTURY GROUP, INC.

(XXII)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
1.870 USD   +1.08%
05/2722ND CENTURY GROUP (NASDAQ : XXII) to Participate in LD Micro, Roth Capital Investor Meetings
GL
05/2722ND CENTURY GROUP (NASDAQ : XXII) to Participate in LD Micro, Roth Capital Investor Meetings
AQ
05/2522nd Century Group, Inc. announced that it has received funding
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
1.78(c) 1.7(c) 1.83(c) 1.85(c) 1.87(c) Last
666 502 810 783 1 039 036 589 394 632 803 Volume
-0.56% -4.49% +7.65% +1.09% +1.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 40,4 M - -
Net income 2022 -35,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,70x
Yield 2022 -
Sales 2023 65,7 M - -
Net income 2023 -29,9 M - -
Net Debt 2023 - - -
P/E ratio 2023 -10,7x
Yield 2023 -
Capitalization 308 M 308 M -
Capi. / Sales 2022 7,62x
Capi. / Sales 2023 4,68x
Nbr of Employees 76
Free-Float 96,5%
More Financials
Company
22nd Century Group, Inc. is an agricultural biotechnology and intellectual property company. The Company is focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. In tobacco, hemp/cannabis, and hop plants, it uses various plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life... 
Sector
Tobacco
Calendar
06/16 | 10:00amShareholder meeting
More about the company
Ratings of 22nd Century Group, Inc.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about 22ND CENTURY GROUP, INC.
05/2722ND CENTURY GROUP (NASDAQ : XXII) to Participate in LD Micro, Roth Capital Investor Meeti..
GL
05/2722ND CENTURY GROUP (NASDAQ : XXII) to Participate in LD Micro, Roth Capital Investor Meeti..
AQ
05/2522nd Century Group, Inc. announced that it has received funding
CI
05/2322ND CENTURY GROUP (NASDAQ : XXII) Announces John J. Miller Joins Its Tobacco Business
GL
05/2322ND CENTURY GROUP (NASDAQ : XXII) Announces John J. Miller Joins Its Tobacco Business
AQ
05/2322nd Century Group Announces John J. Miller Joins Its Tobacco Business
CI
05/1822ND CENTURY GROUP, INC. : Entry into a Material Definitive Agreement, Completion of Acqui..
AQ
05/1822ND CENTURY GROUP (NASDAQ : XXII) Begins Integration of GVB Biopharma, Creating a Complet..
GL
05/1822ND CENTURY GROUP (NASDAQ : XXII) Begins Integration of GVB Biopharma, Creating a Complet..
AQ
05/1822nd Century Group, Inc. Begins Integration of GVB Biopharma, Creating a Complete, Robu..
CI
05/1322nd Century Group Acquires Cannabis Firm GVB Biopharma
MT
05/1322ND CENTURY GROUP (NASDAQ : XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company
GL
05/1322nd Century Group, Inc. announced a financing transaction
CI
05/1322nd Century Group, Inc. acquired GVB BioPharma for $56.2 million.
CI
05/05TRANSCRIPT : 22nd Century Group, Inc., Q1 2022 Earnings Call, May 05, 2022
CI
More news
News in other languages on 22ND CENTURY GROUP, INC.
05/23Le 22nd Century Group annonce l'arrivée de John J. Miller dans son secteur du tabac
05/1822nd Century Group, Inc. Commence l'intégration de GVB Biopharma, créant ainsi une plat..
05/1322nd Century Group acquiert la société de cannabis GVB Biopharma
05/1322ND CENTURY GROUP, INC. (NASDAQCM : XXII) a acquis GVB BioPharma pour 51,7 millions de do..
05/0522nd Century Group, Inc. annonce ses résultats pour le premier trimestre clos le 31 mar..
More news
Analyst Recommendations on 22ND CENTURY GROUP, INC.
More recommendations
Chart 22ND CENTURY GROUP, INC.
Duration : Period :
22nd Century Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends 22ND CENTURY GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,87 $
Average target price 5,50 $
Spread / Average Target 194%
EPS Revisions
Managers and Directors
James A Mish Chief Executive Officer & Director
Michael J. Zercher President & Chief Operating Officer
Richard F. Fitzgerald Chief Financial Officer
Nora B. Sullivan Chairman
Juan Sanchez Tamburrino Vice President-Research & Development